Showing 1071-1080 of 1211 results for "".
- Prism Vision Group Acquires Three New Practiceshttps://modernod.com/news/prism-vision-group-acquires-three-new-practices/2480398/PRISM Vision Group announced that it has recently acquired Bethlehem Eye Associates in Bethlehem, Pennsylvania; Schefkind Eye Care with two locations in Alexandria, Virginia; and Carabin Eye Care in New Milford, New Jersey. Terms of the deals were not disclosed.
- Novartis to Present New Data Highlighting Recent Safety-Specific Beovu Studies at EURETINA 2021https://modernod.com/news/novartis-to-present-new-data-highlighting-recent-safety-specific-beovu-studies-at-euretina-2021/2479502/At the upcoming EURETINA 2021 Virtual Congress, Novartis will present new data highlighting safety-specific Beovu studies, including: The Safety-Specific, Next-Generation Optical Coherence Tomography Analysis from HAWK: Preliminary Qualitative OCT Findings Associated with I
- Samsung Bioepis Announces Results From Post-Hoc Analysis of Phase 3 Study of Ranibizumab Biosimilar Byoovizhttps://modernod.com/news/samsung-bioepis-announces-results-from-post-hoc-analysis-of-phase-3-study-of-ranibizumab-biosimilar-byooviz/2479497/Samsung Bioepis announced results from a post-hoc and subgroup analysis of phase 3 clinical study of Byooviz (ranibizumab biosimilar) identifying the baseline factors associated with visual acuity and anatomical outcomes at both primary endpoints through week 52. The study results will be present
- ARVO Women’s Leadership Development Program Welcomes Class of 2021https://modernod.com/news/arvo-womens-leadership-development-program-welcomes-class-of-2021/2479483/The Association for Research in Vision and Ophthalmology (ARVO) recognized the 2021 class of its Women’s Leadership Development Program (WLDP). The program, provided through the support of Aerie Pharmaceuticals, is an interactive, year-long learning experience focused on leadership skill developm
- AxeroVision Announces Phase 2 Results for Dry Eye Disease Creamhttps://modernod.com/news/axerovision-announces-phase-2-results-for-axr-270-for-treatment-of-dry-eye-disease-associated-with-mgd/2479478/AxeroVision announced positive results from a phase 2 investigational treatment of AXR-270, the company’s novel, proprietary, once-daily glucocorticoid cream, in patients with signs and symptoms of dry eye disease (DED) associated with meibomian gland dysfunction (MGD). I
- Bausch + Lomb Launches Biotrue Hydration Boost Lubricant Eye Drops and Biotrue Micellar Eyelid Cleansing Wipeshttps://modernod.com/news/bausch-lomb-launches-biotrue-hydration-boost-lubricant-eye-drops-and-biotrue-micellar-eyelid-cleansing-wipes/2479359/Bausch + Lomb announced the US launch of Biotrue Hydration Boost Lubricant Eye Drops and Biotrue Micellar Eyelid Cleansing Wipes. Both products are preservative-free and formulated with naturally inspired ingredients to relieve symptoms associated with irritated, dry eyes. “One of the majo
- Bausch + Lomb Completes Enrollment of Second Phase 3 Study for NOV03https://modernod.com/news/bausch-lomb-completes-enrollment-of-second-phase-3-study-for-nov03/2479349/Bausch + Lomb and Novaliq announced the second of two phase 3 (MOJAVE) studies evaluating the investigational drug NOV03 (perfluorohexyloctane) as a first-in-class eye drop with a novel mechanism of action to treat the signs and symptoms of dry eye disease (DED) associated with meibomian gland dy
- Iveric Bio to Present Zimura GATHER2 Enrollment and Retention Updates and New GATHER1 Post-Hoc Analyseshttps://modernod.com/news/iveric-bio-to-present-zimura-gather2-enrollment-and-retention-updates-and-new-gather1-post-hoc-analyses/2479306/Iveric bio announced that today at the company’s Virtual Symposium for Investors and Analysts, Arshad M. Khanani, MD, MA, of Sierra Eye Associates, and Chairman of the GATHER2 Steering Committee, will discuss an accelerated enrollment timeline and patient retention, including injection fidelity,
- Randy Jackson, Patient Advocates to Share Stories of Managing Eye Health While Thriving With Diabetes During Live Virtual Eventhttps://modernod.com/news/randy-jackson-patient-advocates-to-share-stories-of-managing-eye-health-while-thriving-with-diabetes-during-live-virtual-event/2479286/“Focus on Diabetes,” a multi-year eye health initiative with the American Diabetes Association (ADA), VSP Vision Care, and Regeneron, will host a virtual live event, “The Real Stories Behind our Vision,” featuring Grammy-winning musician, producer Randy Jackson. Mr.
- Oyster Point Announces Preclinical Study Results and Pipeline Expansion With ETF Gene Therapy for Ocular Surface Diseaseshttps://modernod.com/news/oyster-point-announces-preclinical-study-results-and-pipeline-expansion-with-etf-gene-therapy-for-ocular-surface-diseases/2479258/Oyster Point Pharma announced the expansion of its pipeline with the introduction of Enriched Tear Film (ETF) Gene Therapy and proof-of-concept in vivo study results from its first gene therapy candidate, OC-101. ETF Gene Therapy is a proprietary adeno-associated virus (AAV) based